ENGAGE- 501: phase II study of entinostat (SNDX-275) in relapsed and refractory Hodgkin lymphoma

Classical Hodgkin lymphoma treatment is evolving rapidly with high response rates from antibody-drug conjugates targeting CD30 and immune checkpoint antibodies. However, most patients do not achieve a complete response, therefore development of novel therapies is warranted to improve patient outcome...

Cijeli opis

Spremljeno u:
Bibliografski detalji
Izdano u:Haematologica
Glavni autori: Batlevi, Connie Lee, Kasamon, Yvette, Bociek, R. Gregory, Lee, Peter, Gore, Lia, Copeland, Amanda, Sorensen, Rachel, Ordentlich, Peter, Cruickshank, Scott, Kunkel, Lori, Buglio, Daniela, Hernandez-Ilizaliturri, Francisco, Younes, Anas
Format: Artigo
Jezik:Inglês
Izdano: Ferrata Storti Foundation 2016
Teme:
Articles
Online pristup:https://ncbi.nlm.nih.gov/pmc/articles/PMC4967576/
https://ncbi.nlm.nih.gov/pubmed/27151994
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.3324/haematol.2016.142406
Oznake: Dodaj oznaku
Bez oznaka, Budi prvi tko označuje ovaj zapis!

Similar Items